2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14909R
    Bardoxolone (Standard)
    		Inhibitor
    Bardoxolone (Standard) is the analytical standard of Bardoxolone (HY-14909). This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury.
    Bardoxolone (Standard)
  • HY-125033S1
    EIDD-1931-d2
    EIDD-1931-d2 is the deuterium labeled 3,6-Dichloro-2-methoxybenzoic acid.
    EIDD-1931-d<sub>2</sub>
  • HY-145530
    (S)-Hydroxychloroquine sulfate
    		Control
    (S)-Hydroxychloroquine ((S)-HCQ) sulfate is an isomer of Hydroxychloroquine (HY-W031727). (S)-Hydroxychloroquine sulfate (2.5-20 mg/mL) reduces the rate of insulin degradation in liver homogenates isolated from non-diabetic and diabetic rats. Formulations containing Hydroxychloroquine have been used in the study of malaria, rheumatoid arthritis, and systemic lupus erythematosus.
    (S)-Hydroxychloroquine sulfate
  • HY-100442S
    Paquinimod-d5
    		Inhibitor
    Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.
    Paquinimod-d<sub>5</sub>
  • HY-183661
    SCHEMBL12616233
    		Inhibitor
    SCHEMBL12616233 is a SARS-CoV-2 main protease (MPro) inhibitor. SCHEMBL12616233 binds to the active cavity of SARS-CoV-2 MPro and forms a stable complex. SCHEMBL12616233 can be used for the research of covid-19.
    SCHEMBL12616233
  • HY-123185
    (Rac)-Z-FA-FMK
    		Inhibitor
    (Rac)-Z-FA-FMK is the racemate of Z-FA-FMK. (Rac)-Z-FA-FMK is an inhibitor of cathepsin B with a Ki of 1.5 μM. (Rac)-Z-FA-FMK inhibits caspase-2, -3, -6, -7, and -9 with IC50s of 6.147, 15.41, 32.45, 9.077, and 110.7 μM. (Rac)-Z-FA-FMK inhibits the main protease of SARS-CoV-2 replication with an IC50 of 11.39 μM. (Rac)-Z-FA-FMK inhibits the increased IL-1β level induced by LPS and NF-κB transactivation in macrophages.
    (Rac)-Z-FA-FMK
  • HY-100575R
    Acriflavine (Standard)
    		Inhibitor
    Acriflavine (Standard) is the analytical standard of Acriflavine (HY-100575). This product is intended for research and analytical applications. Acriflavine (Acriflavinium chloride) is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine is an antiseptic agent. Acriflavine is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2.
    Acriflavine (Standard)
  • HY-176229
    Mpro/Cathepsin L-IN-2
    		Inhibitor
    Mpro/Cathepsin L-IN-2 (Compound 1) is a dual irreversible inhibitor of SARS-CoV-2 main protease (Mpro, pIC50=8.61) and human cathepsin L (hCTSL, pIC50=7.64). Mpro/Cathepsin L-IN-2 is promising for research of COVID-19 and other coronavirus infections.
    Mpro/Cathepsin L-IN-2
  • HY-17367R
    Atazanavir (Standard)
    		Inhibitor
    Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.
    Atazanavir (Standard)
  • HY-180129
    SARS-CoV-2-IN-120
    		Inhibitor
    SARS-CoV-2-IN-120 (Compound S22) is a SARS-CoV-2-specific entry inhibitor. SARS-CoV-2-IN-120 binds and trimerizes within the apex cavity of the SARS2 spike trimer. SARS-CoV-2-IN-120 blocks RBD-ACE2 interaction. SARS-CoV-2-IN-120 neutralizes BA.2 and subsequent Omicron variants. SARS-CoV-2-IN-120 inhibits SARS-CoV-2 replication in mice.
    SARS-CoV-2-IN-120
  • HY-175015
    SARS-CoV-2 Mpro-IN-46
    		Inhibitor
    SARS-CoV-2 Mpro-IN-46 (Compound 12) is a SARS-CoV-2 main protease inhibitor with an IC50 of ∼25 μM. SARS-CoV-2 Mpro-IN-46 has potent antiviral activity with low cytotoxicity against SARS-CoV-2 (IC50: 7.4 μM). SARS-CoV-2 Mpro-IN-46 can be used for coronaviruses COVID-19 research.
    SARS-CoV-2 Mpro-IN-46
  • HY-122668
    K22
    		Inhibitor 98.46%
    K22 is an anti-Coronaviral compound. K22 reduces double-stranded RNA. K22 displays antiviral activity beyond the Coronavirinae subfamily, namely against nidoviruses of the Torovirinae subfamily (EToV and WBV) and members of the Arteriviridae family (PRRSV, EAV). K22 displays antiviral activity against HCoV-229E.
    K22
  • HY-181641
    SARS-CoV-2 PLpro-IN-6
    		Inhibitor
    SARS-CoV-2 PLpro-IN-6 is an irreversible SARS-CoV-2 papain-like protease inhibitor with an IC50 value of 0.059 μM. SARS-CoV-2 PLpro-IN-6 exhibits antiviral activity and can be used in studies related to COVID-19.
    SARS-CoV-2 PLpro-IN-6
  • HY-169200
    SARS-CoV-2 Mpro-IN-26
    		Inhibitor
    SARS-CoV-2 Mpro-IN-26 (compund 13) is a covalent inhibitor of SARS-CoV-2 Mpro.
    SARS-CoV-2 Mpro-IN-26
  • HY-17443R
    Sivelestat (Standard)
    Sivelestat (Standard) is the analytical standard of Sivelestat. This product is intended for research and analytical applications. Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
    Sivelestat (Standard)
  • HY-178188
    TPG-20A
    		Inhibitor
    TPG-20A is a SARS-CoV-2 main protease inhibitor with an IC50 of 27.8 nM. TPG-20A also inhibits MERS-CoV main protease. TPG-20A can be used for the research of infection, such as SARS-CoV-2.
    TPG-20A
  • HY-163186
    SARS-CoV-2 Mpro-IN-13
    		Inhibitor
    SARS-CoV-2 Mpro-IN-13 (compound 20j) is a covalent SARS-CoV-2 Protease Mpro inhibitor with an IC50 value of 19.0 nM. SARS-CoV-2 Mpro-IN-13 processes antiviral activity with an EC50 value of 138.1 nM.
    SARS-CoV-2 Mpro-IN-13
  • HY-180791
    SARS-CoV-2-IN-121
    		Inhibitor
    SARS-CoV-2-IN-121 (Compound 74) is a SARS-CoV-2 virus inhibitor. SARS-CoV-2-IN-121 exhibits IC50 values in the pseudovirus and live virus systems of 1.6 and 0.45 μM respectively. SARS-CoV-2-IN-121 effectively inhibits the replication or protein expression of the virus within cells and has almost no toxicity to host cells. SARS-CoV-2-IN-121 can be used for SARS-CoV-2 virus infection research.
    SARS-CoV-2-IN-121
  • HY-162111
    SARS-CoV-2-IN-73
    		Inhibitor
    SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker.
    SARS-CoV-2-IN-73
  • HY-17430S2
    Amprenavir-13C6
    		Inhibitor
    Amprenavir-13C6 (VX-478-13C6) is 13C labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir-<sup>13</sup>C<sub>6</sub>
Cat. No. Product Name / Synonyms Species Source